Latest Unoprostone Stories
TOKYO, Aug. 25 /PRNewswire/ -- We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R) eye-drops) in patients with retinitis pigmentosa has been completed. We submitted the notification of the clinical trial in August 2008. Enrollment in the phase 2 study began at six clinical sites in late December 2008 and was completed on August 3, 2009. The clinical study has progressed with...
- A spider.
- Figuratively, a peevish, testy, ill-natured person.